Last reviewed · How we verify
NCT04062747
The Effect Of I-Gel And Ambu Aura-I Use On Laryngofaryngeal Mucosa
NA trial testing I-gel in Mucosal Damage in 40 participants. Status unknown.
15 September 2019
Quick facts
| Lead sponsor | Bezmialem Vakif University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | screening |
| Enrollment | 40 |
| Start date | 18 May 2019 |
| Primary completion | 15 September 2019 |
| Estimated completion | 20 September 2019 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- I-gel
- Ambu aura i
Conditions studied
- Mucosal Damage — all drugs for Mucosal Damage →
Sponsor
Bezmialem Vakif University
Who can join
Under 2, any sex, with Mucosal Damage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Supraglottic airway devices (SGADs) are frequently preferred in surgical surgery for pediatric patients. i-gel LMA (laryngeal mask airway) and Ambu Aura-i LMA are the new generation supraglottic airway devices. The aim of this study was to compare airway trauma and postoperative complications due to i-gel and Ambu Aura in infants. In the study patients were divided into two groups performed on minor surgery ASA I (American Society of Anesthesiologists score) and 40 infants. After standard anesthesia i-Gel was placed into a group and Ambu Aura-i was placed to the other. Flexible bronchoscopy was performed at the end of surgery. Mucosal damage and postoperative complications in laryngopharyngeal structures were compared.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04062747
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of I-gel
Trials testing the same drug.
- NCT07196696 — An in Vivo CT Imaging Study of GMA-Tulip, I-gel, and LMA Supreme (GLAM-II) · NA · recruiting
- NCT06545903 — Supraglottic Airways for Entrapped Trauma Patients · NA · completed
- NCT06177769 — Comparison of Supraglottic Airway Devices in EBUS · completed
- NCT06853756 — Gastric Insufflation Volume Using I-gel Versus Ambu AuraGain in Pediatric Patients Undergoing Elective Orthopedic Operat · NA · recruiting
- NCT05523752 — Insertion of Different Supraglottic Airway Devices on Manikin · NA · completed
Other Bezmialem Vakif University trials
Trials by the same sponsor.
- NCT07369297 — PULP SENSIBILITY AND MASSETER INHIBITORY REFLEX IN DIABETIC POLYNEUROPATHY · not yet recruiting
- NCT07433595 — Association Between Child and Parental Stress and Bruxism in Children Aged 8-11 Years · not yet recruiting
- NCT07443111 — Comparison of Virtual Reality-Based and Routine Preoperative Education on Surgical Anxiety and Salivary Cortisol · NA · not yet recruiting
- NCT07421349 — Comparison of Pulmonary Functions and Respiratory Muscle Strength Between Children With Hearing Impairment and Healthy P · not yet recruiting
- NCT07414615 — Aerobic Training in Lower Extremity Lymphedema · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04062747 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bezmialem Vakif University
- Last refreshed: 20 August 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04062747.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing